ArticleThe journal of sexual medicine2009
Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism.
Article in The journal of sexual medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 76 citations in OpenAlex.
- Update on the prevalence and pathophysiology of sickle cell priapism: a narrative review.International journal of impotence research · 2026Review
- Sickle Cell Disease and Male Infertility: Pathophysiological Mechanisms, Clinical Manifestations, and Fertility Preservation Strategies-A Narrative Review.Life (Basel, Switzerland) · 2026Review
- An update on mechanisms and treatment options for priapism.Nature reviews. Urology · 2025Review
- Idiopathic recurrent ischemic priapism: a review of current literature and an algorithmic approach to evaluation and management.Basic and clinical andrology · 2024Article
- Soluble guanylate cyclase stimulators and activators: new horizons in the treatment of priapism associated with sickle cell disease.Frontiers in pharmacology · 2024Review
- Zuclopenthixol Induced Ischemic Priapism: Case Report and Review of Literature.Journal of family & reproductive health · 2023Article
- Enuresis and overactive bladder in sickle cell patients: a narrative review of the literature.World journal of urology · 2023Review
- Clinical Vignettes Part I.Hematology/oncology clinics of North America · 2022Review
- A visualization system for erectile vascular dynamics.Frontiers in cell and developmental biology · 2022Article
- Article
- Molecular Profile of Priapism Associated with Low Nitric Oxide Bioavailability.Journal of proteome research · 2018Article
- Effect of lysyl oxidase (LOX) on corpus cavernous fibrosis caused by ischaemic priapism.Journal of cellular and molecular medicine · 2018Article
- Article
- Ischemic priapism: Can eosinophil count and platelet functions be positive predictive factors in etiopathogenesis.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017Article
- Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.The journal of sexual medicine · 2015Article
- Nitrergic Mechanisms for Management of Recurrent Priapism.Sexual medicine reviews · 2015Article
- How I treat priapism.Blood · 2015Article
- Molecular pathophysiology of priapism: emerging targets.Current drug targets · 2015Review
- Management of priapism: an update for clinicians.Therapeutic advances in urology · 2014Review
- Excess adenosine A2B receptor signaling contributes to priapism through HIF-1α mediated reduction of PDE5 gene expression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
introductionPriapism is a poorly understood disease process with little information on the etiology and pathophysiology of this erectile disorder. One group of patients with a high prevalence of priapism is men with sickle-cell disease.
aimEstablish an in vivo transgenic sickle-cell mouse model to study the pathophysiology of sickle-cell disease-associated priapism.
methodsTransgenic sickle-cell disease mice, expressing human sickle hemoglobin, were utilized. Three groups of mice were used: (i) wild type (WT), (ii) sickle-cell heterozygotes (Hemi), and (ii) sickle-cell homozygotes (Sickle). Two age groups of each cohort of mice were utilized: young adult (4-6 months) and aged (18-22 months).
main outcome measuresHistological (trichrome stain to measure ratio of collagen to smooth muscle), penile hydroxyproline content (collagen content), and transmission electron microscopic analysis of WT, Hemi, and Sickle mice penes, as well as in vivo erectile responses [change in intracavernous pressure (ICP)] to cavernous nerve stimulation (CNS), were determined. The frequency of erectile responses (erections/hour) pre- and poststimulation was also measured in each of the experimental groups.
resultsSickle mice had increased (P < 0.05) collagen to smooth muscle ratio and hydroxyproline content in the penis when compared with WT and Hemi mice penes. Transmission electron microscopy demonstrated thickened smooth muscle cell bundles, disruption of the endothelial lining of the corporal sinusoids, and increased (P < 0.05) caveolae number. Sickle mice had significantly (P < 0.05) higher ICP to CNS and increased (P < 0.05) frequency of erections pre- and post-CNS when compared with WT and Hemi mice erectile responses. Sickle mice did develop ED (change in ICP in response to CNS) with increasing age.
conclusionThe morphometric changes of the penis and exaggerated in vivo erectile responses support the use of this transgenic sickle-cell disease animal model to study the pathophysiological mechanisms involved in sickle-cell disease-associated priapism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.